SADI Bariatric Surgery: How It Works and What to Expect

SADI bariatric surgery, or Single Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy (SADI-S), is a specialist weight-loss operation that combines stomach reduction with an intestinal bypass to limit both food intake and calorie absorption. Developed as a less complex alternative to the biliopancreatic diversion with duodenal switch, it is performed laparoscopically at specialist NHS and private bariatric centres. This article explains how SADI-S works, who may be eligible, what results to expect, the risks involved, and what recovery typically looks like, with reference to NICE guidance and UK clinical standards.

What is SADI bariatric surgery and how does it work?

SADI-S combines a sleeve gastrectomy with a single duodeno-ileal bypass, restricting stomach volume and reducing intestinal absorption of calories and nutrients. It is performed laparoscopically and governed by NICE Interventional Procedures Guidance.

SADI bariatric surgery, which stands for Single Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy (also written SADI-S), is a two-component weight-loss operation that combines a sleeve gastrectomy with a single intestinal bypass to reduce both food intake and calorie absorption. The procedure was developed as a simplified alternative to the biliopancreatic diversion with duodenal switch (BPD-DS), aiming to achieve comparable outcomes with a lower surgical complexity.

During the operation, a surgeon first removes roughly 80 per cent of the stomach, creating a narrow, sleeve-shaped pouch.^[6] The first part of the small intestine (the duodenum) is then divided just beyond the stomach outlet and reconnected to a lower section of the small bowel (the ileum), bypassing a significant length of intestine. This single connection, or anastomosis, is what gives the procedure its name.

The sleeve component restricts the volume of food the stomach can hold, producing earlier satiety. The bypass component reduces the length of intestine available to absorb calories and nutrients, particularly fats. These mechanisms are also associated with hormonal changes, including alterations in gut hormones such as GLP-1, which are thought to help regulate appetite and blood glucose levels, though the precise contribution of each mechanism continues to be studied.

SADI-S is performed laparoscopically (keyhole surgery) in most centres, which generally means smaller incisions, reduced blood loss and a shorter hospital stay compared with open surgery. In terms of complexity, it is broadly comparable to a Roux-en-Y gastric bypass and less complex than a full BPD-DS, though this varies by centre and surgical experience. Importantly, NICE has issued Interventional Procedures Guidance on SADI-S, and NHS centres offering the procedure are expected to follow special governance, consent and audit arrangements as set out in that guidance.^[1][2] It is typically offered at specialist bariatric centres with appropriate multidisciplinary teams.

Who is eligible for SADI surgery on the NHS?

NHS eligibility follows NICE CG189, generally requiring a BMI of 40 kg/m² or above, or 35 to 39.9 kg/m² with a significant obesity-related condition, with referral via Tier 3 or Tier 4 weight-management services.

NHS eligibility for bariatric surgery is guided by NICE clinical guideline CG189 (Obesity: identification, assessment and management), with individual Integrated Care Boards (ICBs) making local commissioning decisions about which specific procedures they fund. Not all ICBs commission SADI-S, and patients should check with their local service.

Under NICE CG189, bariatric surgery is generally recommended for adults with a BMI of 40 kg/m² or above, or a BMI of 35 to 39.9 kg/m² with a significant obesity-related condition such as type 2 diabetes, hypertension or obstructive sleep apnoea. NICE also recommends considering surgery for people with a BMI of 30 to 34.9 kg/m² who have recent-onset type 2 diabetes, where this is likely to be in remission with surgical intervention. Lower BMI thresholds may apply for some people from minority ethnic backgrounds, in whom obesity-related health risks occur at lower body weights; clinicians should refer to the NICE guidance for the relevant thresholds.

Because SADI-S is a more complex and malabsorptive procedure, it tends to be considered for patients with a higher BMI, those who have not achieved adequate results with less extensive surgery, or those with conditions such as severe type 2 diabetes that may benefit particularly from the metabolic effects of intestinal bypass. Some centres offer SADI-S as a revision procedure for patients who have regained weight following a previous sleeve gastrectomy.

Referral is usually made through locally commissioned Tier 3 or Tier 4 specialist weight-management services rather than directly from a GP to a surgeon. Before being listed for surgery, patients are typically required to:

• Demonstrate that non-surgical weight management approaches have been tried and have not produced sufficient results

• Undergo a comprehensive assessment by a multidisciplinary team including a dietitian, psychologist, physician and surgeon

• Be medically fit for general anaesthesia and major abdominal surgery

• Commit to long-term follow-up and nutritional supplementation

Because SADI-S is performed under NICE Interventional Procedures Guidance, NHS centres must ensure that patients receive full information about the evidence base and that outcomes are recorded as part of audit arrangements.

Private access to SADI-S is also available through specialist bariatric centres. Patients seeking information about weight-management pathways, including surgical and non-surgical options, can speak with a clinician at Bolt Pharmacy, a GPhC-registered UK online pharmacy offering weight-management consultations with prescriber review and pharmacist support. Eligibility for any treatment is always determined on an individual clinical basis.

What results can you expect in terms of weight loss and health?

Published cohort data report mean excess weight loss broadly in the range of 80 to 90 per cent at one to two years, alongside improvements in type 2 diabetes, blood pressure, sleep apnoea and other obesity-related conditions.

SADI-S surgery produces substantial weight loss, with published cohort studies and registry data reporting mean excess weight loss broadly in the range of 80 to 90 per cent at one to two years in many series, though individual outcomes vary considerably depending on starting weight, the length of intestine bypassed (the common channel length), adherence to dietary guidance and follow-up care.^[8][11] It is important to note that outcome figures differ between studies depending on whether excess weight loss or total weight loss is used as the measure, and on the duration of follow-up. Patients should discuss realistic expectations with their surgical team, who can refer to current registry data such as that from the National Bariatric Surgery Registry (NBSR) or international IFSO registry reports.

Longer-term data suggest that weight loss may be better maintained after SADI-S than after sleeve gastrectomy alone, partly because the malabsorptive component continues to limit calorie absorption, though head-to-head comparative studies are still accumulating and results vary by centre protocol.

Beyond weight reduction, SADI-S has been associated with meaningful improvements in obesity-related health conditions in observational studies. Type 2 diabetes remission rates are among the most studied outcomes, with several cohort series reporting remission or significant improvement in a substantial proportion of patients with pre-existing diabetes; this effect is attributed to both weight loss and the direct metabolic impact of bypassing the proximal small bowel.^[9][11] Remission definitions and follow-up intervals vary between studies, so patients should discuss what outcomes are realistic for their individual situation. Improvements have also been reported in:

• Blood pressure and cardiovascular risk markers

• Obstructive sleep apnoea

• Joint pain and mobility

• Non-alcoholic fatty liver disease

• Polycystic ovary syndrome (PCOS) in women of reproductive age

These improvements are largely based on observational evidence, and outcomes depend heavily on long-term lifestyle changes, including dietary modification and regular physical activity. Patients who do not engage with post-operative support programmes tend to achieve less durable outcomes. The procedure also carries a risk of nutritional deficiencies (discussed in the following section), which can affect overall health if not proactively managed. Realistic expectations, set in collaboration with the surgical team before the operation, are an important part of the consent process.

What are the risks and side effects you should know about?

SADI-S carries risks of anastomotic leak, bile reflux, marginal ulceration, internal hernia and serious nutritional deficiencies requiring lifelong supplementation and monitoring. Seek emergency care for severe abdominal pain, chest pain or signs of collapse.

SADI-S carries both general surgical risks and specific risks related to its malabsorptive design, and patients should discuss these thoroughly with their surgical team before consenting to the procedure. As with any major abdominal operation under general anaesthesia, there are risks of bleeding, infection, blood clots (deep vein thrombosis and pulmonary embolism), anaesthetic complications and, rarely, death. Leak from the anastomosis or the staple line of the sleeve is a serious but uncommon complication that may require further surgery.

Specific risks associated with the single-anastomosis design include bile reflux into the stomach or oesophagus and marginal ulceration at the anastomosis site. Most centres advise patients to take a proton pump inhibitor (PPI) after surgery and to avoid non-steroidal anti-inflammatory drugs (NSAIDs) and smoking, which increase ulcer risk. Internal hernia, where a loop of bowel passes through a gap created during surgery, is another recognised complication that can present with abdominal pain and requires urgent assessment.

The malabsorptive component of SADI-S means that nutritional deficiencies are a significant and ongoing concern. Because a substantial length of small intestine is bypassed, absorption of fat-soluble vitamins (A, D, E and K), vitamin B12, iron, calcium and protein can all be reduced. Without lifelong supplementation and regular blood monitoring, deficiencies can lead to anaemia, bone disease (including osteoporosis), neurological problems and poor wound healing. Patients must commit to taking prescribed supplements every day for the rest of their lives, following the regimen recommended by their bariatric team, which is typically guided by British Obesity and Metabolic Surgery Society (BOMSS) standards.

Protein-calorie malnutrition is a specific risk after malabsorptive surgery. Patients who cannot maintain adequate protein intake may require dietetic input, supplemental nutrition or, in severe cases, surgical revision. High protein intake is a lifelong priority.

Thiamine (vitamin B1) deficiency can develop rapidly in patients who experience prolonged vomiting or very poor oral intake after surgery. Thiamine deficiency can cause serious neurological complications including Wernicke's encephalopathy. Patients who are vomiting persistently should seek urgent medical attention; healthcare professionals should consider thiamine replacement before giving glucose-containing fluids.

Rapid weight loss after surgery increases the risk of gallstone formation. Some centres prescribe ursodeoxycholic acid for a period after surgery to reduce this risk; patients should follow their own team's protocol. Kidney stone risk may also be increased after malabsorptive surgery, and adequate hydration is important.

Other side effects that patients commonly report include:

• Changes in bowel habit, including looser stools or increased frequency

• Malodorous wind, which can be socially disruptive

• Dumping syndrome (nausea, flushing and diarrhoea after eating sugary or fatty foods)

• Reflux symptoms in some individuals

• Hair thinning in the months following surgery, usually temporary

Medication absorption can be significantly altered after malabsorptive surgery. Modified-release formulations and medicines with a narrow therapeutic index may not be absorbed reliably. Patients should have their medicines reviewed by their prescriber or pharmacist after surgery, and should not crush or alter formulations without professional advice.

Patients with pre-existing diabetic eye disease should inform their surgical team, as rapid improvement in blood glucose control can be associated with transient worsening of pre-existing or pre-proliferative diabetic retinopathy, and ophthalmological review may be appropriate.^[23][24]

Pregnancy and contraception: women of reproductive age are advised to avoid pregnancy for at least 12 to 18 months after surgery, while weight is still changing rapidly and nutritional status is being established.^[22] Malabsorption can reduce the reliability of oral contraceptive pills, and long-acting reversible contraception (LARC) such as an intrauterine device or implant is generally preferred.^[20][21] Women planning a pregnancy after bariatric surgery should discuss preconception planning with their surgical team and GP, as close nutritional monitoring is important.

Know when to seek urgent help. Contact 999 or go to the nearest emergency department immediately if you experience chest pain, shortness of breath, severe or rapidly worsening abdominal pain, pain in the shoulder tip, high fever, or signs of collapse. These may indicate a serious complication such as a leak, pulmonary embolism or internal hernia. Contact your surgical team or NHS 111 urgently for persistent vomiting, signs of dehydration, or symptoms suggestive of nutritional deficiency such as extreme fatigue, numbness, tingling or visual changes.

Suspected side effects from any medicines used in the peri-operative period can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What does recovery look like after SADI surgery?

Hospital stay is typically two to four days, with a structured dietary progression from fluids to solids over six to eight weeks. Lifelong annual blood tests and bariatric team follow-up are essential to monitor nutritional status.

Recovery after SADI-S surgery typically begins with a hospital stay of two to four days, though this varies depending on the individual's health, any complications and the centre's protocols. Most patients are encouraged to mobilise on the day of surgery to reduce the risk of blood clots, and are discharged once they are tolerating fluids, their pain is controlled and there are no signs of early complications.

The dietary progression after SADI-S follows a structured plan overseen by a specialist bariatric dietitian. The stages below are a general example only; patients must follow the specific plan provided by their own surgical team, as protocols vary between centres. A typical progression might be:

• Weeks 1 to 2: Clear fluids only

• Weeks 3 to 4: Pureed or blended foods

• Weeks 5 to 6: Soft, moist foods

• From around week 6 to 8: Gradual return to a modified solid diet

Protein intake is prioritised at every stage to support healing and preserve muscle mass. Patients are advised to eat slowly, chew thoroughly, avoid drinking with meals and stop eating as soon as they feel full.

Most people who have desk-based or light work can return to employment within two to four weeks, while those with physically demanding jobs may need six weeks or longer. These are approximate guides; individual recovery varies. For driving, patients should check both with their insurer and with DVLA guidance on fitness to drive after surgery, as no fixed return-to-driving timeframe applies universally. As a general principle, patients should be off strong pain relief and able to perform an emergency stop comfortably before driving.

Long-term follow-up is essential. In UK practice, this typically involves review by the bariatric centre team at intervals during the first one to two years, with ongoing shared care and annual blood tests in primary care thereafter for life. Blood tests should monitor nutritional status including vitamins A, D, E and K, vitamin B12, iron, calcium, full blood count and protein levels, in line with BOMSS postoperative monitoring recommendations. Checks are commonly arranged at around three months, six months and twelve months after surgery, and then annually.

Patients should contact their GP or surgical team if they experience persistent vomiting, severe abdominal pain, signs of infection, or symptoms suggestive of nutritional deficiency such as extreme fatigue, numbness or visual changes. NHS 111 is available for urgent advice outside of GP hours.

Scientific References

1. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) for treating morbid obesity – HTG423 (PDF resource).
2. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy – Interventional Procedure Overview (evidence final PDF).
3. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy – Interventional Procedure Consultation Document.
4. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy – Overview document.
5. Overweight and obesity management – Medicines and surgery (NG246).
6. How weight loss surgery is done.
7. Recovering from weight loss surgery.
8. Mid-term 4-Year Outcomes with Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy.
9. Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S): short-term outcomes similar to duodenal switch.
10. Long-term 10-year outcomes of biliopancreatic diversion (including SADI-S comparison).
11. The Efficacy and Safety of Laparoscopic SADI-S in Mid- and Long-Term Follow-Up: a Systematic Review.
12. Roux-En-Y Gastric Bypass Versus Sleeve Gastrectomy Plus Procedures: Systematic Review and Meta-Analysis.
13. Comparison of different revisional surgeries after sleeve gastrectomy: A network meta-analysis.
14. Comparative seven year outcomes of RYGB and SADI-S as revisional procedures for weight recurrence after sleeve gastrectomy.
15. Wernicke encephalopathy in non-alcoholic patients following gastrointestinal procedures: a systematic review.
16. Acute nutritional axonal neuropathy and Wernicke's encephalopathy status post Roux-en-Y gastric bypass.
17. Acute non-alcoholic nutritional neuropathies in high-income countries – a systematic review.
18. Efficacy of prophylactic ursodeoxycholic acid in preventing gallstone formation after metabolic bariatric surgery: updated systematic review and meta-analysis.
19. Ursodeoxycholic Acid Prophylaxis and the Reduction of Gallstone Formation After Bariatric Surgery: An Updated Meta-Analysis of Randomized Controlled Trials.
20. The use of contraception for patients after bariatric surgery.
21. Bariatric surgery in women of reproductive age: special concerns for pregnancy.
22. Impact of Surgery-to-Conception Interval on Maternal and Perinatal Outcomes Following Laparoscopic Sleeve Gastrectomy: A Retrospective Cohort Study.
23. Short-Term and Long-Term Effects of Bariatric Surgery on Diabetic Retinopathy: A Systematic Review.
24. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review.

Frequently Asked Questions